Peripheral Blood Eosinophilia Has a Favorable Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 4, 2009, Pages 471-482

  Kim, Dong Hwan ^a,c   Popradi, Gizelle ^a   Xu, Wei ^b   Gupta, Vikas ^a   Kuruvilla, John ^a   Wright, Janice ^a   Messner, Hans A ^a   Lipton, Jeffrey H ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Allogeneic peripheral blood stem cell transplantation; GVHD; Humoral immunity; Peripheral eosinophilia; Th2 cytokine pathway

Indexed keywords

ANTINUCLEAR ANTIBODY; CYCLOSPORIN A; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; EOSINOPHILIA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PREVALENCE; PROGNOSIS; RELAPSE; TH2 CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; EOSINOPHILIA; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; INCIDENCE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TH2 CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 61849178766     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.01.003     Document Type: Article

References (42)

1. McNeel D., Rubio M.T., Damaj G., et al. Hypereosinophilia as a presenting sign of acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation 74 (2002) 1797-1800
2. Jacobsohn D.A., Schechter T., Seshadri R., Thormann K., Duerst R., and Kletzel M. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation 77 (2004) 1096-1100
3. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204-217
4. Przepiorka D., Anderlini P., Saliba R., et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 98 (2001) 1695-1700
5. Daneshpouy M., Socie G., Lemann M., Rivet J., Gluckman E., and Janin A. Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease. Blood 99 (2002) 3033-3040
6. Tanaka J., Imamura M., Kasai M., et al. Th2 cytokines (IL-4, IL-10 and IL-13) and IL-12 mRNA expression by concanavalin A-stimulated peripheral blood mononuclear cells during chronic graft-versus-host disease. Eur J Haematol 57 (1996) 111-113
7. Tanaka J., Imamura M., Kasai M., et al. The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease. Bone Marrow Transplant 19 (1997) 571-576
8. Bates M.E., Bertics P.J., and Busse W.W. IL-5 activates a 45-kilodalton mitogen-activated protein (MAP) kinase and Jak-2 tyrosine kinase in human eosinophils. J Immunol 156 (1996) 711-718
9. Bates M.E., Liu L.Y., Esnault S., et al. Expression of interleukin-5- and granulocyte macrophage-colony-stimulating factor-responsive genes in blood and airway eosinophils. Am J Respir Cell Mol Biol 30 (2004) 736-743
10. Aisa Y., Mori T., Nakazato T., et al. Blood eosinophilia as a marker of favorable outcome after allogeneic stem cell transplantation. Transpl Int 20 (2007) 761-770
11. Sato T., Kobayashi R., Nakajima M., Iguchi A., and Ariga T. Significance of eosinophilia after stem cell transplantation as a possible prognostic marker for favorable outcome. Bone Marrow Transplant 36 (2005) 985-991
12. Kim D.H., Jamal N., Saragosa R., et al. Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. Biol Blood Marrow Transplant 13 (2007) 1233-1243
13. Pond G.R., Lipton J.H., and Messner H.A. Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population. Biol Blood Marrow Transplant 12 (2006) 422-429
14. Gupta V., Daly A., Lipton J.H., et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 11 (2005) 764-772
15. Kiss T.L., Panzarella T., Messner H.A., et al. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 31 (2003) 73-78
16. Messner H.A. Long-term outcome of allogeneic transplants in acute myeloid leukemia. Leukemia 16 (2002) 751-752
17. Kim D.H., Messner H., Minden M., et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis (2007)
18. Deeg H.J. How I treat refractory acute GVHD. Blood 109 (2007) 4119-4126
19. Morris E.S., and Hill G.R. Advances in the understanding of acute graft-versus-host disease. Br J Haematol 137 (2007) 3-19
20. Parimon T., Au D.H., Martin P.J., and Chien J.W. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 144 (2006) 407-414
21. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
22. Akpek G., Zahurak M.L., Piantadosi S., et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 97 (2001) 1219-1226
23. Akpek G., Lee S.J., Flowers M.E., et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood 102 (2003) 802-809
24. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23 (2005) 1993-2003
25. Ozawa S., Nakaseko C., Nishimura M., et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol 137 (2007) 142-151
26. van den Brink M.R., Moore E., Ferrara J.L., and Burakoff S.J. Graft-versus-host-disease-associated thymic damage results in the appearance of T cell clones with anti-host reactivity. Transplantation 69 (2000) 446-449
27. Fallen P.R., McGreavey L., Madrigal J.A., et al. Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients. Bone Marrow Transplant 32 (2003) 1001-1014
28. Lister J., Messner H., Keystone E., Miller R., and Fritzler M.J. Autoantibody analysis of patients with graft versus host disease. J Clin Lab Immunol 24 (1987) 19-23
29. Patriarca F., Skert C., Sperotto A., et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 34 (2006) 389-396
30. Quaranta S., Shulman H., Ahmed A., et al. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin Immunol 91 (1999) 106-116
31. Wechalekar A., Cranfield T., Sinclair D., and Ganzckowski M. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin Lab Haematol 27 (2005) 247-249
32. Ferrara J.L. Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors. J Hematother Stem Cell Res 9 (2000) 299-306
33. Krenger W., and Ferrara J.L. Dysregulation of cytokines during graft-versus-host disease. J Hematother 5 (1996) 3-14
34. Krenger W., and Ferrara J.L. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res 15 (1996) 50-73
35. Daneshpouy M., Facon T., Jouet J.P., and Janin A. Acute flare-up of conjunctival graft-versus-host disease with eosinophil infiltration in a patient with chronic graft-versus-host disease. Leuk Lymphoma 43 (2002) 445-446
36. Okamoto M., Okano A., Akamatsu S., et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 20 (2006) 172-173
37. Ellison C.A., Bradley D.S., Fischer J.M., Hayglass K.T., and Gartner J.G. Murine graft-versus-host disease induced using interferon-gamma-deficient grafts features antibodies to double-stranded DNA, T helper 2-type cytokines and hypereosinophilia. Immunology 105 (2002) 63-72
38. Via C.S., Shustov A., Rus V., Lang T., Nguyen P., and Finkelman F.D. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 167 (2001) 6821-6826
39. Williamson E., Garside P., Bradley J.A., More I.A., and Mowat A.M. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease. J Immunol 159 (1997) 1208-1215
40. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11 (2005) 945-956
41. Jagasia M., Giglia J., Chinratanalab W., et al. Incidence and outcome of chronic graft-versus-host disease (cGVHD) using National Institute of Health (NIH) criteria. Blood 108 (2006) 816a
42. Couriel D.R., Saliba R., Escalon M.P., et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 130 (2005) 409-417